» Articles » PMID: 23557563

Transplantation of Neural Stem Cells Overexpressing Glial Cell Line-derived Neurotrophic Factor Enhances Akt and Erk1/2 Signaling and Neurogenesis in Rats After Stroke

Overview
Specialty General Medicine
Date 2013 Apr 6
PMID 23557563
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Our previous studies have indicated that the beneficial effects of grafting neural stem cells (NSCs) overexpressing glial cell line-derived neurotrophic factor (GDNF) in rats after stroke. However, the underlying mechanisms are highly debatable. In this study, we investigated whether neurogenesis, Akt, and extracellular signal-regulated kinase 1/2 (Erk1/2) signaling were involved in this process.

Methods: Transient ischemic stroke were induced by occluding middle cerebral artery for 2 hours and reperfusion. At 3 days after reperfusion, GDNF/NSCs, NSCs, and vehicle were administered. Immunohistochemical staining was used to evaluate neurogenesis by nestin antibody; phosphorylation of Akt and Erk1/2 was investigated by Western blotting analysis.

Results: Transplantation of GDNF/NSCs and NSCs significantly increased nestin-positive cells compared to control group (vehicle) from 1 to 7 weeks after reperfusion, and GDNF/NSCs showed stronger effect than NSCs at 2 and 3 weeks after reperfusion. Meanwhile, enhanced phosphorylation level of Erk1/2 was observed in the GDNF/NSCs and NSCs groups compared with control group, and phosphorylation level of Erk1/2 in GDNF/NSCs group was remarkably higher than that of NSCs group at any given time. In contrast, expression of mitogen-activated protein kinase phosphatase-1 (MKP-1), known as inhibitor of Erk1/2 signaling, was significantly decreased in the GDNF/NSCs and NSCs groups compared with the control group. Moreover, much enhanced and prolonged phosphorylation level of Akt of GDNF/NSCs group was detected compared with control and NSCs group.

Conclusion: Grafting GDNF/NSCs enhances neurogenesis and activates Akt and Erk1/2 signaling, that may provide the potential for GDNF/NSCs in stroke treatment.

Citing Articles

Current knowledge and challenges associated with targeted delivery of neurotrophic factors into the central nervous system: focus on available approaches.

Bahlakeh G, Rahbarghazi R, Mohammadnejad D, Abedelahi A, Karimipour M Cell Biosci. 2021; 11(1):181.

PMID: 34641969 PMC: 8507154. DOI: 10.1186/s13578-021-00694-2.


Neural Stem Cells for Early Ischemic Stroke.

Hamblin M, Lee J Int J Mol Sci. 2021; 22(14).

PMID: 34299322 PMC: 8306669. DOI: 10.3390/ijms22147703.


Potential Mechanisms and Perspectives in Ischemic Stroke Treatment Using Stem Cell Therapies.

Zhou G, Wang Y, Gao S, Fu X, Cao Y, Peng Y Front Cell Dev Biol. 2021; 9:646927.

PMID: 33869200 PMC: 8047216. DOI: 10.3389/fcell.2021.646927.


Effects of primary microglia and astrocytes on neural stem cells in and models of ischemic stroke.

Wen S, Zheng X, Liu L, Li N, Mao H, Huang L Neural Regen Res. 2021; 16(9):1677-1685.

PMID: 33510055 PMC: 8328755. DOI: 10.4103/1673-5374.306093.


A Novel Endogenous Damage Signal, CSF-2, Activates Multiple Beneficial Functions of Adipose Tissue-Derived Mesenchymal Stem Cells.

Park S, Cho A, Kim J, Lee H, Hong I Mol Ther. 2019; 27(6):1087-1100.

PMID: 30962162 PMC: 6554530. DOI: 10.1016/j.ymthe.2019.03.010.